[go: up one dir, main page]

MA40657B2 - Composition pharmaceutique stable comprenant du pemetrexed ou un sel pharmaceutiquement acceptable de celui-ci - Google Patents

Composition pharmaceutique stable comprenant du pemetrexed ou un sel pharmaceutiquement acceptable de celui-ci

Info

Publication number
MA40657B2
MA40657B2 MA40657A MA40657A MA40657B2 MA 40657 B2 MA40657 B2 MA 40657B2 MA 40657 A MA40657 A MA 40657A MA 40657 A MA40657 A MA 40657A MA 40657 B2 MA40657 B2 MA 40657B2
Authority
MA
Morocco
Prior art keywords
pemetrexed
pharmaceutically acceptable
pharmaceutical composition
acceptable salt
stable pharmaceutical
Prior art date
Application number
MA40657A
Other languages
English (en)
Other versions
MA40657A1 (fr
Inventor
Mi-Won Sohn
Sun-Woo Jang
Dong-Han Won
Yong-Min Kim
Hyung-Don Hwang
Dong-Hun Min
Original Assignee
Dong A St Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dong A St Co Ltd filed Critical Dong A St Co Ltd
Publication of MA40657A1 publication Critical patent/MA40657A1/fr
Publication of MA40657B2 publication Critical patent/MA40657B2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une composition d'une solution injectable prête à l'emploi comprenant du pemetrexed ou des sels pharmaceutiquement acceptables de ceux-ci, comprenant : du pemetrexed ; du sulfite de sodium anhydre ; et de la n-acétyl-l-cystéine. Relativement à une utilisation en tant que préparation injectable, la composition d'une solution injectable prête à l'emploi comprenant le pemetrexed de la présente invention est appropriée pour une administration efficace de pemetrexed étant donné q
MA40657A 2014-11-17 2015-11-06 Composition pharmaceutique stable comprenant du pemetrexed ou un sel pharmaceutiquement acceptable de celui-ci MA40657B2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020140160225A KR101770605B1 (ko) 2014-11-17 2014-11-17 페메트렉시드 또는 그것의 약제학적으로 허용가능 한 염을 함유하는 안정한 약제학적 조성물
PCT/KR2015/011905 WO2016080687A1 (fr) 2014-11-17 2015-11-06 Composition pharmaceutique stable comprenant du pemetrexed ou un sel pharmaceutiquement acceptable de celui-ci

Publications (2)

Publication Number Publication Date
MA40657A1 MA40657A1 (fr) 2018-06-29
MA40657B2 true MA40657B2 (fr) 2021-10-29

Family

ID=56014166

Family Applications (1)

Application Number Title Priority Date Filing Date
MA40657A MA40657B2 (fr) 2014-11-17 2015-11-06 Composition pharmaceutique stable comprenant du pemetrexed ou un sel pharmaceutiquement acceptable de celui-ci

Country Status (6)

Country Link
US (1) US20170340638A1 (fr)
EP (1) EP3222271A4 (fr)
JP (1) JP6236165B2 (fr)
KR (1) KR101770605B1 (fr)
MA (1) MA40657B2 (fr)
WO (1) WO2016080687A1 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2399124A1 (fr) * 2000-02-04 2001-08-09 Eli Lilly And Company Composition pharmaceutique comprenant le pemetrexed avec le monothioglycerol, la cysteine l ou l'acide thioglycolique
WO2012015810A2 (fr) 2010-07-28 2012-02-02 Eagle Pharmaceuticals, Inc. Compositions pharmaceutiques contenant du pemetrexed présentant une stabilité en stockage prolongé
KR20130122065A (ko) * 2012-04-30 2013-11-07 씨제이제일제당 (주) 페메트렉시드를 함유하는 안정화된 주사용 액상 제제
KR101260636B1 (ko) * 2012-11-29 2013-05-13 씨제이제일제당 (주) 안정화된 페메트렉시드 제제
KR101485243B1 (ko) * 2013-05-08 2015-01-21 씨제이헬스케어 주식회사 안정화된 페메트렉시드 제제

Also Published As

Publication number Publication date
JP2017504646A (ja) 2017-02-09
MA40657A1 (fr) 2018-06-29
KR20160058564A (ko) 2016-05-25
KR101770605B1 (ko) 2017-08-23
US20170340638A1 (en) 2017-11-30
EP3222271A4 (fr) 2018-05-16
EP3222271A1 (fr) 2017-09-27
WO2016080687A1 (fr) 2016-05-26
JP6236165B2 (ja) 2017-11-22

Similar Documents

Publication Publication Date Title
MA46101A (fr) Modulateurs allostériques positifs du récepteur muscarinique m1
MX392213B (es) Composiciones farmacéuticas que comprenden sales de glicopirrolato y 1,1-difluoroetano.
CR20220251A (es) Nuevos derivados de metilquinazolinona
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
EA201892119A1 (ru) Лекарственный препарат, полученный путем комбинирования агониста fxr и arb
AR095034A1 (es) El uso de los agonistas del receptor 2 del péptido formilo para el tratamiento de las enfermedades inflamatorias oculares
MA37866B1 (fr) Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur
MA38390A1 (fr) Composés tétrahydropyrrolothiazines
EA202190960A1 (ru) Конденсированные пирролины, которые действуют как ингибиторы убиквитин-специфической протеазы 30 (usp30)
MA38865A1 (fr) Formulation comprenant un agent hypolipidémiant
MA52424B1 (fr) Compositions pharmaceutiques comprenant du (2s)--((1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl)-1,4-oxazepane-2-carboxamide
EA201690888A1 (ru) Новые гетероциклические соединения
MA39165A1 (fr) Dérivés de benzimidazole-proline pour leurs utilisations dans le traitement du syndrome des etats crepusculaires
MA38358A1 (fr) Formulations de composés organiques
EA201890534A1 (ru) Новые аннелированные феноксиацетамиды
MA39983A (fr) Dérivés de carboxamide
MA42301B1 (fr) Sel cristallin de fumarate de (s)-[3,4-difluoro-2-(2-fluoro-4-iodophénylamino)phényl][3-hydroxy-3-(pipéridin-2-yl)azétidin-1-yl]-méthanone
MA43913A (fr) Modulateurs allostériques positifs du récepteur m1 muscarinique
EA201692298A1 (ru) Производные карбоксамидов
MA46039B1 (fr) Dérivé de triazolopyrazinone utile en tant qu'inhibiteur de pde1 humain
EA201890684A1 (ru) Производные фториндола в качестве положительных аллостерических модуляторов мускаринового рецептора m1
PH12022551415A1 (en) Liquid pharmaceutical composition of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n-methylmethanamine
EA201990550A1 (ru) Офтальмологический препарат, включающий азоловое соединение
MA45639B1 (fr) Combinaison d'antagonistes purs du récepteur 5-ht6 avec des inhibiteurs d'acétylcholinestérase
MA40657B2 (fr) Composition pharmaceutique stable comprenant du pemetrexed ou un sel pharmaceutiquement acceptable de celui-ci